Empowering Scalable 3.2T/6.4T Scale-Up Optical Connectivity Solutions for the AI Era This optical engine highlights ...
Praxis Precision Medicines Inc. (NASDAQ:PRAX) submitted two NDAs to the FDA for ulixacaltamide, aimed at treating essential tremor, and relutrigine, for specific pediatric epileptic encephalopathies.
Explore NMDA receptor modulation and its critical role in neuronal development and cognitive functions like learning and ...
Modulator pills transformed cystic fibrosis care. But the fight for a cure is not over — so long as research remains funded.
The flip-chip octal-channel transmitter integrates laser sources, high-speed modulators, and programmable optical equalization in a compact engine for hyperscale deployment at 3.2Tbps DR8 connectivity ...
Scorpions, having inhabited the Earth long before the emergence of humans, represent an ancient lineage of arthropods. While often regarded with fear due to their potential to induce severe pain or ...
When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the treatment of human disease. At the time, that ...
Ion channels are integral membrane proteins that regulate the passage of ions across cell membranes, thereby shaping processes as diverse as neuronal signaling, muscle contraction, and hormone ...
The lithium niobate thin-film modulator was designed to achieve a modulation frequency of 350 kHz within the 0–2π phase range, further realizing high-speed control of optical field coherence. Credit: ...
Praxis Precision Medicines has received Breakthrough Therapy Designation (BTD) from the FDA for relutrigine, a sodium channel modulator intended for pediatric treatment of SCN2A and SCN8A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results